Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
preladenant + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Preladenant + pembrolizumab is an investigational combination therapy studied primarily for the treatment of advanced solid tumors resistant to prior therapy. Preladenant is a potent and selective competitive antagonist of the adenosine A2A receptor, while pembrolizumab is a monoclonal antibody checkpoint inhibitor targeting the programmed cell death-1 (PD-1) receptor. The combination is designed to simultaneously block adenosine-mediated immunosuppression (via A2A receptor antagonism with preladenant) and enhance immune response against tumors by inhibiting PD-1-mediated immune checkpoint signaling (via pembrolizumab). This approach aims to improve anti-tumor immunity in patients with select advanced malignancies. The combination is currently being evaluated in clinical trials, particularly in Phase Ib/II studies for advanced solid tumors[1][2][3].
- Other names
- preladenant + pembrolizumabpreladenant (MK-3814A) + pembrolizumab (MK-3475)
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ADORA2A (Adenosine A₂A Receptor)
Beyond the preview
Go deeper on preladenant + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on preladenant + pembrolizumab.